SCHOLAR ROCK HOLDING CORPORATION Operating Cash Flow
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Cash Flow of -$152.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$70.31M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$82.10M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$75.50M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$68.92M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for fiscal 2025 was -$300.04M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for fiscal 2024 was -$200.95M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for fiscal 2023 was -$145.23M.
- SCHOLAR ROCK HOLDING CORPORATION net cash provided by (used in) operating activities for fiscal 2022 was -$132.69M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$70.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$152.41M 10-Q · filed 2026-08-06 | -$227.90M derived: sum of 3 quarters · filed 2026-08-06 | -$296.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$82.10M 10-Q · filed 2026-05-07 | -$157.60M derived: sum of 2 quarters · filed 2026-05-07 | -$226.52M derived: sum of 3 quarters · filed 2026-05-07 | -$303.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$75.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$144.42M derived: sum of 2 quarters · filed 2026-03-03 | -$221.36M derived: sum of 3 quarters · filed 2026-08-06 | -$300.04M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$68.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$145.86M derived: sum of 2 quarters · filed 2026-08-06 | -$224.54M 10-Q · filed 2025-11-14 | -$274.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$76.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$155.62M 10-Q · filed 2026-08-06 | -$205.13M derived: sum of 3 quarters · filed 2026-08-06 | -$257.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$78.67M 10-Q · filed 2026-05-07 | -$128.19M derived: sum of 2 quarters · filed 2026-05-07 | -$180.64M derived: sum of 3 quarters · filed 2026-05-07 | -$229.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$49.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$101.97M derived: sum of 2 quarters · filed 2026-03-03 | -$151.16M derived: sum of 3 quarters · filed 2026-03-03 | -$200.95M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$52.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$101.65M derived: sum of 2 quarters · filed 2025-11-14 | -$151.44M 10-Q · filed 2025-11-14 | -$188.78M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$49.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$98.98M 10-Q · filed 2025-08-06 | -$136.33M derived: sum of 3 quarters · filed 2025-08-06 | -$168.60M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$49.78M 10-Q · filed 2025-05-14 | -$87.13M derived: sum of 2 quarters · filed 2025-05-14 | -$119.41M derived: sum of 3 quarters · filed 2025-05-14 | -$151.96M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$37.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$69.62M derived: sum of 2 quarters · filed 2025-02-27 | -$102.17M derived: sum of 3 quarters · filed 2025-02-27 | -$145.23M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$32.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$64.82M derived: sum of 2 quarters · filed 2024-11-12 | -$107.88M 10-Q · filed 2024-11-12 | -$136.78M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$32.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$75.60M 10-Q · filed 2024-08-08 | -$104.51M derived: sum of 3 quarters · filed 2024-08-08 | -$130.99M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$43.05M 10-Q · filed 2024-05-07 | -$71.96M derived: sum of 2 quarters · filed 2024-05-07 | -$98.44M derived: sum of 3 quarters · filed 2024-05-07 | -$133.18M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$28.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$55.39M derived: sum of 2 quarters · filed 2024-03-19 | -$90.13M derived: sum of 3 quarters · filed 2024-03-19 | -$132.69M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$26.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$61.22M derived: sum of 2 quarters · filed 2023-11-07 | -$103.79M 10-Q · filed 2023-11-07 | -$136.24M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$34.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$77.30M 10-Q · filed 2023-08-09 | -$109.76M derived: sum of 3 quarters · filed 2023-08-09 | -$145.74M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$42.56M 10-Q · filed 2023-05-09 | -$75.02M derived: sum of 2 quarters · filed 2023-05-09 | -$111.00M derived: sum of 3 quarters · filed 2023-05-09 | -$142.81M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$32.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$68.43M derived: sum of 2 quarters · filed 2023-03-07 | -$100.25M derived: sum of 3 quarters · filed 2023-03-07 | -$126.79M 10-K · filed 2023-03-07 |
| 2021-09-30 | -$35.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$67.79M derived: sum of 2 quarters · filed 2022-11-14 | -$94.33M 10-Q · filed 2022-11-14 | -$114.02M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$31.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$58.36M 10-Q · filed 2022-08-08 | -$78.04M derived: sum of 3 quarters · filed 2022-08-08 | -$101.44M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$26.54M 10-Q · filed 2022-05-16 | -$46.23M derived: sum of 2 quarters · filed 2022-05-16 | -$69.62M derived: sum of 3 quarters · filed 2022-05-16 | -$89.45M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$19.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$43.08M derived: sum of 2 quarters · filed 2022-03-07 | -$62.91M derived: sum of 3 quarters · filed 2022-03-07 | -$60.27M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$23.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$43.22M derived: sum of 2 quarters · filed 2021-11-09 | -$40.59M 10-Q · filed 2021-11-09 | -$56.65M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$19.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$17.19M 10-Q · filed 2021-08-10 | -$33.26M derived: sum of 3 quarters · filed 2021-08-10 | -$48.37M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $2.64M 10-Q · filed 2021-05-13 | -$13.43M derived: sum of 2 quarters · filed 2021-05-13 | -$28.54M derived: sum of 3 quarters · filed 2021-05-13 | -$44.95M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$16.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$31.18M derived: sum of 2 quarters · filed 2021-03-09 | -$47.59M derived: sum of 3 quarters · filed 2021-03-09 | -$63.12M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$15.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$31.52M derived: sum of 2 quarters · filed 2020-11-09 | -$47.05M 10-Q · filed 2020-11-09 | $8.05M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$16.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$31.94M 10-Q · filed 2020-08-07 | $23.16M derived: sum of 3 quarters · filed 2020-08-07 | $14.14M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$15.53M 10-Q · filed 2020-05-07 | $39.56M derived: sum of 2 quarters · filed 2020-05-07 | $30.55M derived: sum of 3 quarters · filed 2020-05-07 | $18.93M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $55.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $46.08M derived: sum of 2 quarters · filed 2020-03-12 | $34.45M derived: sum of 3 quarters · filed 2020-03-12 | $24.57M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$9.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$20.64M derived: sum of 2 quarters · filed 2019-11-12 | -$30.52M 10-Q · filed 2019-11-12 | -$36.58M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$11.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$21.51M 10-Q · filed 2019-08-14 | -$27.57M derived: sum of 3 quarters · filed 2019-08-14 | -$33.31M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$9.88M 10-Q · filed 2019-05-15 | -$15.94M derived: sum of 2 quarters · filed 2019-05-15 | -$21.69M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | -$6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | -$11.80M derived: sum of 2 quarters · filed 2019-03-19 | -$21.74M 10-K · filed 2019-03-19 | |
| 2017-09-30 | -$5.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$15.68M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$9.93M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |